Pharmaceuticals

Panlong Pharmaceutical

Panlong Pharmaceutical released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 299.42 M, actual EPS CNY 0.0636

Panlong Pharmaceutical released FY2025 earnings on April 27 After-Market (BJT), actual revenue CNY 1.141 B (forecast CNY 1.854 B), actual EPS CNY 0.92

Panlong Pharmaceutical released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 222.54 M, actual EPS CNY 0.21

Panlong Pharmaceutical FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

Panlong Pharmaceutical to Release FY2025 Earnings on April 28 After-Market (BJT), Forecast Revenue CNY 1.854 B

Panlong Pharmaceutical released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 267.43 M, actual EPS CNY 0.28

Panlong Pharmaceutical released FY2025 9 Months earnings on October 27 After-Market BJT, actual revenue CNY 841.45 M, actual EPS CNY 0.8503

Panlong Pharmaceutical to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

Panlong Pharmaceutical released FY2025 Semi-Annual earnings on August 27 After-Market BJT, actual revenue CNY 574.02 M, actual EPS CNY 0.57

Panlong Pharmaceutical released FY2025 Q2 earnings on August 27 After-Market BJT, actual revenue CNY 323.81 M, actual EPS CNY 0.2703

Panlong Pharmaceutical to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Dunlong Pharmaceutical Introduces Progress of Innovative Drug R&D and Exclusive Medicines

Panda Dragon Pharmaceutical Obtained CNAS Laboratory Accreditation Certificate

Pandaura Pharmaceuticals Holds 2024 Annual Report Earnings Conference

Panlong Responds to Impact of National Medical Procurement and Proposes Countermeasures

Pannom Pharmaceutical Announces 2024 Annual Report and Q1 2025 Report

Panlongqi Tablets Lead Market Share in Segmented Area

Pandaura Pharmaceutical Reports 8.91% YoY Net Profit Growth in 2024

Panlong Pharmaceutical released FY2024 earnings on April 24 Pre-Market (BJT), actual revenue CNY 973.86 M (forecast CNY 1.498 B), actual EPS CNY 1.15

Panlong Pharmaceutical released FY2024 Q4 earnings on April 24 Pre-Market (BJT), actual revenue CNY 256.94 M, actual EPS CNY 0.3003

000554

301111

002493

002728

002864

Chinese medicine stocks opened sharply higher, with Panlong Pharmaceutical and TY PHAR. hitting the daily limit, and Bio Valley and LSPG rising over 10%. Oil and gas stocks quickly rebounded, with Tong Petrotech rising over 10%, followed by Shandong Molong, TSPC, XZPT, Geo-Jade Petroleum, HBP, and ZPEC. The chemical sector continued to rise during the session, with CZDH, JINNIU CHEMICAL, and BCC hitting the daily limit, and Jiangtian Chemical and Shuangle Co., Ltd. rising over 10%, along with Yuntu Holdings, RSPC, LUXI CHEMICAL, and wanhua

- On February 6, A-shares opened lower, with major indices initially dropping over 1% before recovering, led by active chemical and traditional Chinese medicine stocks, while liquor stocks adjusted.  
- Hong Kong stocks continued to decline, with the Hang Seng Index falling over 1.5%, while the bond market saw fluctuations in government bond futures prices.  
- Commodity markets faced widespread declines, with domestic futures for silver, platinum, and palladium all dropping significantly, although some precious metals showed slight recovery later in the day.

Wallstreetcn

TSPC

LSPG

RSPC

Tong Petrotech

TY PHAR.

Geo-Jade Petroleum

CZDH

JINNIU CHEMICAL

wanhua

XZPT

LUXI CHEMICAL

ZPEC

The A-shares opened lower and rose higher, with all three major indices turning positive. The chemical and electric grid sectors collectively surged, the Hang Seng Index fell over 1%, tech stocks continued to decline, and Shanghai silver dropped over 13%

Chinese medicine stocks opened sharply higher, with Panlong Pharmaceutical and TY PHAR. hitting the daily limit, and Bio Valley and LSPG rising over 10%

600938

600489

600547

02824

09824

159562

82824

The three major A-share indices opened lower by 0.9% to 1.2%, with the Shanghai Composite Index at 4,040 points, the Shenzhen Component Index at 13,801 points, and the ChiNext Index at 3,222 points. Oil and gold stocks generally fell, with the three major oil companies opening down by 1.6% to 2.6%. Gold-related stocks opened lower by nearly 4% to 6.1%. Traditional Chinese medicine stocks rose against the trend, with Panlong Pharmaceutical and TY PHAR. hitting the daily limit. The central parity rate of the RMB against the USD was adjusted down by 20 points, reported at 6.9590

AASTOCKS

CNOOC

ZHONGJIN GOLD

SD-GOLD

EFUND GOLD MI ETF

EFUND GOLD MI-U

ChinaAMC CSI SH-SZ-HK Gold Industry Equity ETF

EFUND GOLD MI-R

E Fund Gold ETF

Huaan Yifu Gold ETF

ChinaAMC Gold ETF

The three major A-share indices of Shanghai and Shenzhen opened lower by 0.9% to 1.2%, with oil and gold stocks weak, while traditional Chinese medicine stocks rose against the trend

600415

002643

000661

On November 4th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 157 million yuan. The specific situation of the restricted share unlocks today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Changchun Gaoxin 000661 Equity Incentive Restricted Circulation 42,900 Yunnai Power 000903 Equity Incentive Restricted Circulation 14,978,800 YIWU CCC 600415 Equity Incentive Restricted Circulation 795,600 Valiant 002643 Equity Incentive Restricted Circulation 7,128,800 Panlong Pharmaceutical 002864 Equity Incentive Restricted Circulation 281,600

Zhitong

YIWU CCC

Valiant

CCHT

Zhitong A-share lock-up release overview | November 4

Panlong Pharmaceutical announced that its revenue for the third quarter was 267 million yuan, a year-on-year increase of 2.24%; net profit was 29.6707 million yuan, a decrease of 0.83%. Revenue for the first three quarters was 841 million yuan, a year-on-year increase of 17.37%; net profit was 89.8059 million yuan, an increase of 0.26%

Panlong Pharmaceutical: The net profit for the third quarter was 29.6707 million yuan, a decrease of 0.83%

On September 29th, Panlong Pharmaceutical stated on the interactive platform that the company currently has no overseas sales business

Panlong Pharmaceutical: The company currently has no overseas sales business

Panlong Pharmaceutical recently announced that its research and development product, Loxoprofen Sodium Gel Patch (PLJT-001), has received the acceptance notice for the marketing authorization application from the National Medical Products Administration. This product is used to treat osteoarthritis, muscle pain, and swelling or pain after injury, with significant anti-inflammatory and analgesic effects, as well as low irritation and good skin compatibility, enhancing the comfort and convenience of medication

Panlong Pharmaceutical: PLJT-001 Loxoprofen Sodium Gel Patch has received the acceptance notice for domestic drug production registration and marketing license

Panlong Pharmaceutical announced that in the first half of 2025, the operating revenue was 574 million yuan, a year-on-year increase of 26.06%. The net profit was 60.1352 million yuan, a year-on-year increase of 0.81%. The company plans to distribute a cash dividend of 1 yuan for every 10 shares based on a total of 106 million shares to all shareholders

Panlong Pharmaceutical: In the first half of 2025, the net profit was 60.1352 million yuan, a year-on-year increase of 0.81%

Panlong Pharmaceutical recently received a notification from the National Medical Products Administration, confirming that its registration clinical trial application for Panlong Qining Gel Patch has been accepted. This product is based on the ancestral secret recipe of Mr. Wang Jiacheng and aims to treat knee osteoarthritis, with effects of promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain. Due to the complexity of research and clinical trials, the progress may be affected by uncertain factors

Panlong Pharmaceutical: Received the acceptance notice for the application of Panlong Qining Gel Patch

Panlong Pharmaceutical(002864.SZ)